Top

Published in:

01-06-2020 | Metastasis | Original Research

Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery

Published in: Journal of Radiation Oncology | Issue 1-2/2020

Abstract

Purpose

Biological subtypes have been strongly correlated with loco-regional recurrence after definitive treatment for localized breast cancer. Brain metastases (BM) occur in 15% of patient diagnosed with breast cancer (BC). Therefore, we sought to determine whether biologic subtype is predictive of local control (LC) in BC patients with BM treated with stereotactic radiosurgery (SRS).

Methods

This is a single-center retrospective study conducted with Institutional Review Board approval for the period January 1, 2004–December 31, 2018. Eligibility criteria included (1) histopathologic proven BC with documented biologic subtype, (2) presence of BM treated with SRS (single fraction), (3) follow-up MRIs, and (4) clinical follow-up. Patients were subdivided into three biologic subtypes: ER+/HER2- (“luminal”), HER2+, and ER-/PR-/HER2 (TN). All patients were treated with LINAC-based SRS with dose according to published guidelines. Cox proportional hazard model and Kaplan-Meier were used for statistical analysis of LC and overall survival (OS).

Results

With a median follow-up of 11.1 months, 17 BC BM in 50 consecutive patients were included in this study. The median disease-specific GPA was 2.0, and all patients received systemic chemotherapy and/or hormonal therapy. The 12-month LC rates for the entire cohort were 85%, 87%, and 49% for luminal, HER2+, and TN, respectively, with a significantly shorter time to local failure for the TN subtype (p = 0.014). The 12-month OS rates were 83%, 88%, and 80% for luminal, HER2+, and TN, respectively, with a trend toward shorter OS in the TN group.

Conclusion

This study shows that in BC patients with BM treated with SRS, biologic subtype affects LC. Consideration of radiation treatment intensification or altered fractionation to improve LC may be indicated for the TN subtype. Further multicenter studies are necessary to corroborate our results.

Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7(3):337–344CrossRefPubMed

Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology 13(7):941–954 57–61; discussion 61–2, 9PubMed

Posner JB (1992) Management of brain metastases. Rev Neurol 148(6–7):477–487PubMed

Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49(4):651–654CrossRefPubMed

Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113CrossRefPubMed

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872CrossRefPubMed

Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMed

Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705CrossRefPubMed

Horton JK, Jagsi R, Woodward WA, Ho A (2018) Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 100(1):23–37CrossRefPubMed

10.

Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Jnci-J Natl Cancer I 106(5)

11.

Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980–1989PubMed

12.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed

13.

Breast Cancer Staging System (2018) AJCC cancer staging manual, Eight Edition

14.

Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160CrossRefPubMed

15.

Millar EK, Graham PH, O'Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701–4708CrossRefPubMed

16.

Wang YH, Yin QG, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498CrossRefPubMed

17.

Merino T, Ip T, Dominguez F et al (2018) Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study. Oncotarget 9(54):30355–30362CrossRefPubMedPubMedCentral

18.

Langlands FE, Horgan K, Dodwell DD, Smith L (2013) Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Brit J Radiol 86(1023)

19.

Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123(12):2283–2293CrossRefPubMed

20.

Buatti JM, Friedman WA, Meeks SL, Bova FJ (2000) RTOG 90-05: the real conclusion. Int J Radiat Oncol Biol Phys 47(2):269–271CrossRefPubMed

21.

Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentral

22.

Lee EW, Wei LJ, Amato DA, Leurgans S (1992) Cox-type regression-analysis for large numbers of small-groups of correlated failure time observations. Nato Adv Sci I E-App 211:237–247

23.

Shtatland ES, Barton MB (1998) An information-gain measure of fit in PROC LOGISTIC. In: Proceedings of the Twenty-Third Annual Sas Users Group International Conference. pp 1195–9

24.

DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918CrossRefPubMed

25.

Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Anna Oncol 20(1):56–62CrossRef

26.

Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894–900CrossRefPubMedPubMedCentral

27.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242–1248CrossRefPubMed

28.

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast Cancer: a population-based study. JAMA Oncol 3(8):1069–1077CrossRefPubMedPubMedCentral

29.

Bastos DCA, Maldaun MVC, Sawaya R et al (2018) Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neuro-Oncol Pract 5(3):161–169CrossRef

30.

Suzuki S, Inoue T, Ishido K (2016) Factors influencing local tumor control after gamma knife radiosurgery for intracranial metastases from breast cancer. J Clin Neurosci 33:154–158CrossRefPubMed

31.

Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM (2012) Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol 83(4):E479–EE86CrossRef

32.

Wen Y, Dai G, Wang L, Fu K, Zuo S (2019) Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells. Biosci Rep 39(3)

33.

Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, Osti M, Enrici RM, Esposito V (2016) Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large ( > 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol 95(4):1142–1148CrossRef

34.

Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent M, Vogelbaum MA, Wen PY, Response Assessment in Neuro-Oncology (RANO) group (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):E270–E2E8CrossRefPubMed

Title: Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery
Publication date: 01-06-2020
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Journal of Radiation Oncology / Issue 1-2/2020
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-020-00424-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1-2/2020

Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma

Radiotherapy for maxillary sinus carcinoma: dosimetric comparison of volumetric modulated arc therapy with 0° and 90° collimator intensity modulated radiation therapy

Recommendations for radiosurgery and stereotactic ablative radiotherapy terminology to guide clinical and research practices for the medical oncologist, radiation oncologist, and surgeon

Long-term outcomes of hypofractionated stereotactic radiotherapy for refractory functional pituitary adenoma

Analysis of setup uncertainties and determine the variation of the clinical target volume (CTV) to planning target volume (PTV) margin for various tumor sites treated with three-dimensional IGRT couch using KV-CBCT

Comparison of ICRU 38 rectal reference point dose estimates with measured dose in vivo in cobalt-60 HDR brachytherapy for cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer